Table 3.

Toxicities of hyper-CVAD and imatinib mesylate in 91 postinduction courses



No. (%)*
Parameter
Grades 1-2
Grades 3-4
Infections (overall)  —   23 (25)  
FUO   —   7 (8)  
Pneumonia   —   6 (7)  
Bacterial   —   3 (3)  
Atypical   —   2 (2)  
Fungal/presumed fungal   —   1 (1)  
Sepsis   —   9 (10)  
GNR bacteremia   —   5 (5)  
Catheter-related bacteremia   —   4 (4)  
Other   —   8 (9)  
Sinusitis   —   3 (3)  
Osteomyelitis   —   2 (2)  
Herpes zoster   —   2 (2)  
Upper respiratory infections (RSV)   —   1 (1)  
Cardiovascular   
Fluid retention   5 (25)   1 (5)  
Arrythmia (supraventricular)   2 (10)   2 (10)  
Deep venous thrombosis   —   2 (10)  
Syncope   —   2 (10)  
Reduction in ejection fraction   2 (10)   —  
Hepatic   
Increase in bilirubin   5 (25)   —  
Increase in transaminases   5 (25)   —  
Neuromuscular   
Fatigue   6 (30)   2 (10)  
Peripheral neuropathy   6 (30)   1 (5)  
Headaches (postlumbar puncture)   2 (10)   2 (10)  
Bone pain   3 (15)   —  
Myalgias   2 (10)   —  
Fracture (femur/vertebral)   —   2 (10)  
Gastrointestinal   
Stomatitis   5 (25)   —  
Constipation   4 (20)   1 (5)  
Diarrhea   2 (10)   2 (10)  
Nausea   2 (10)   1 (5)  
Reflux   1 (5)   2 (10)  
Ileus   —   1 (5)  
Coagulopathy   
Hypofibrinogenemia   2 (10)   1 (5)  
Hemorrhage   
Gastrointestinal   —   1 (5)  
Skin   
Rash   2 (10)   —  
Renal   
Increase in creatinine   5 (25)   —  
Hyponatremia
 

 
1 (5)
 


No. (%)*
Parameter
Grades 1-2
Grades 3-4
Infections (overall)  —   23 (25)  
FUO   —   7 (8)  
Pneumonia   —   6 (7)  
Bacterial   —   3 (3)  
Atypical   —   2 (2)  
Fungal/presumed fungal   —   1 (1)  
Sepsis   —   9 (10)  
GNR bacteremia   —   5 (5)  
Catheter-related bacteremia   —   4 (4)  
Other   —   8 (9)  
Sinusitis   —   3 (3)  
Osteomyelitis   —   2 (2)  
Herpes zoster   —   2 (2)  
Upper respiratory infections (RSV)   —   1 (1)  
Cardiovascular   
Fluid retention   5 (25)   1 (5)  
Arrythmia (supraventricular)   2 (10)   2 (10)  
Deep venous thrombosis   —   2 (10)  
Syncope   —   2 (10)  
Reduction in ejection fraction   2 (10)   —  
Hepatic   
Increase in bilirubin   5 (25)   —  
Increase in transaminases   5 (25)   —  
Neuromuscular   
Fatigue   6 (30)   2 (10)  
Peripheral neuropathy   6 (30)   1 (5)  
Headaches (postlumbar puncture)   2 (10)   2 (10)  
Bone pain   3 (15)   —  
Myalgias   2 (10)   —  
Fracture (femur/vertebral)   —   2 (10)  
Gastrointestinal   
Stomatitis   5 (25)   —  
Constipation   4 (20)   1 (5)  
Diarrhea   2 (10)   2 (10)  
Nausea   2 (10)   1 (5)  
Reflux   1 (5)   2 (10)  
Ileus   —   1 (5)  
Coagulopathy   
Hypofibrinogenemia   2 (10)   1 (5)  
Hemorrhage   
Gastrointestinal   —   1 (5)  
Skin   
Rash   2 (10)   —  
Renal   
Increase in creatinine   5 (25)   —  
Hyponatremia
 

 
1 (5)
 

GNR indicates gram-negative rod;—, not applicable.

*

Incidence of infections episodes/courses; all other toxicities according to occurrence by patient since usually intermittent in nature (no. at risk = 20).

Refer to Table 2 for infections specific for induction (course 1).

Close Modal

or Create an Account

Close Modal
Close Modal